2-Chinolylnitren | 101772-05-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-Chinolylnitren
• 英文别名: 3H-quinolin-3-ylium-2-ylideneazanide
• CAS: 101772-05-8
• 化学式: C₉H₆N₂
• 分子量: 142.16
• InChiKey: SNYXUICUEMLNKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  13.4
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Chinolylnitren 生成 1,3-diazabenzo[d]cyclohepta-1,2,4,6-tetraene
  参考文献：
  名称：

  Kuzaj, Martin; Lueerssen, Holger; Wentrup, Curt, Angewandte Chemie, 1986, vol. 98, # 5, p. 476 - 477

  摘要：

  DOI：

文献信息

• Antimalarial Quinolines and Methods of Use Thereof
  申请人：Wolf Christian

  公开号：US20110045100A1

  公开（公告）日：2011-02-24

  One aspect of the invention relates to substitute quinolines with antimalarial activity, and compositions and kits comprising at least one of them. Another aspect of the invention relates to methods for the treatment or prevention or both of malaria comprising administering to a subject a therapeutically effective amount of such a compound. Importantly, a number of the compounds show excellent potency against both chloroquine-sensitive and chloroquine-resistant strains.

  本发明的一个方面涉及具有抗疟活性的替代喹啉，以及包含至少其中之一的组合物和试剂盒。另一个方面涉及用这种化合物向受试者施用治疗有效量的方法，以治疗或预防疟疾。重要的是，其中一些化合物对氯喹敏感和氯喹耐药菌株都表现出极高的效力。
• Photochromic hydrazone switches
  申请人：THE TRUSTEES OF DARTMOUTH COLLEGE

  公开号：US11279677B2

  公开（公告）日：2022-03-22

  Provided herein are compounds for use as photochromic molecular switches having very long thermal isomerization half-lives and switchable fluorescence properties both in solution and the solid state.

  本文所提供的化合物可用作光致变色分子开关，具有极长的热异构化半衰期以及在溶液和固态下均可切换的荧光特性。
• PHOTOCHROMIC HYDRAZONE SWITCHES
  申请人：Trustees of Dartmouth College

  公开号：EP3535348A1

  公开（公告）日：2019-09-11
• COMPOUND DERIVED FROM QUINOLINE, USE OF A COMPOUND, COMPOSITION AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF A CONDITION CAUSED BY A BLOOD PARASITE
  申请人：FUNDÃÇAO OSWALDO CRUZ

  公开号：US20220332685A1

  公开（公告）日：2022-10-20

  Despite recent efforts to eradicate malaria worldwide, this parasitic disease is still considered a major public health problem, with a total of 219 million malaria cases and 435,000 deaths in 2017 After a decade of use, however, resistance to CQ has emerged in some locations, including Southeast Asia, South America, and the Western Pacific region, spreading progressively into malaria-endemic areas, including Africa, where increases in malaria mortality have been observed. This has led, in recent years, to the adoption of artemisinin-based combination therapies. Artemisinin-based combination therapies remain effective in most parts of the world, but recent cases of resistance in Southeast Asia call for new approaches and especially new drugs to treat malaria. Thus, the present invention features CQ analogues of Formula (I) that exhibited high activity against CQ-sensitive and CQ-resistant blood parasites and were also active in mice. The present invention also provides pharmaceutical compositions comprising the compounds of Formula (I), use of said compounds, and methods for treating conditions caused by blood parasites.
• US4997839A
  申请人：——

  公开号：US4997839A

  公开（公告）日：1991-03-05